https://botanixpharma.com/wp-content/uploads/BOT_FB_Update.png 788 940 Haley Chartres /wp-content/uploads/botanix-logo.png Haley Chartres2020-11-11 01:24:232023-03-13 21:16:45BTX 1801 Update
BTX 1801 Update
Botanix (ASX:BOT) has today announced it has secured a clear development path from the FDA for its BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting.
Our team will have more clinical data to share soon too – our BTX 1801 Phase 2a study in Perth is fully enrolled and remains on track for completion before the end of this calendar year.
Read today’s ASX release here.